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SUMMARY
Objective: To investigate the impact of second-trimester maternal serum screening on prenatal diagnosis of
Down syndrome and the use of amniocentesis in the Taiwanese population.
Materials and Methods: From 1990 to 2000, 166,419 amniocenteses were analyzed cytogenetically in the
Taiwanese population. Among these, 58.85% were for advanced maternal age, 4.5% for abnormal ultrasound
findings, 26.17% for abnormal maternal serum screening results, 1.82% for a previous child with congenital
anomaly, 1.02% for a family history of chromosome aberrations, and 7.63% for other purposes. Chromosome
aberrations were detected in 4,217 cases (2.53%), of which 1,277 (30.28%) were Down syndrome. Of the
Down syndrome cases, 65.86% were detected by amniocentesis for advanced maternal age, 5.95% for abnormal
ultrasound findings, 21.14% for abnormal maternal serum screening results, 1.25% for a previous child with
congenital anomaly, 1.18% for a family history of chromosome aberrations, and 4.62% for other purposes.
Results: There was a prominent increase in the number of women undergoing amniocentesis in the Taiwanese
population between 1990 and 2000. There was an 8.9-fold increase in the number undergoing amniocentesis
for advanced maternal age, a 6.3-fold increase in that for abnormal ultrasound findings, a 46.2-fold increase
in that for abnormal maternal serum screening results, a 2.9-fold increase in that for a previous child with
congenital anomaly, a 5.6-fold increase in that for a family history of chromosome aberrations, and a 4.4-
fold increase in that for other purposes. There was also a 35.7-fold increase in the number of prenatally detected
Down syndrome cases, from seven in 1990 to 250 in 2000. The highest rates of Down syndrome were found
in cases with abnormal ultrasound findings (1/99 tests). Down syndrome was 0.72-fold as common in
amniocenteses performed because of positive serum screening results (1/161 tests) compared with the rate
seen in the advanced maternal age group (1/116 tests). The detection rates increased from 1/449 tests in
1990, through 1/198 tests, 1/203 tests, 1/158 tests, 1/215 tests, 1/229 tests, 1/169 tests, 1/143 tests,
1/90 tests, 1/92 tests, to 1/123 tests in 2000.
Conclusion: Both the number of women undergoing amniocentesis and the number of detected cases of Down
syndrome increased during these years. Amniocentesis in this population no longer led to a significant
improvement in the detection rate of Down syndrome. In view of the effective use of amniocentesis as a diagnostic
procedure for Down syndrome, efforts should be made to use more efficient prenatal screening programs and
to reduce the number of unnecessary amniocenteses. [Taiwanese J Obstet Gynecol 2005;44(1):31–35]
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Introduction
Genetic amniocentesis is the most common invasive
diagnostic procedure for prenatal diagnosis of fetal
aneuploidy. Although advanced maternal age remains
the most common indication for genetic amniocentesis,
the introduction of maternal serum biochemistry
screening has led to a growing number of amniocen-
teses. The impact of second-trimester maternal serum
screening on prenatal diagnosis of Down syndrome and
on the use of amniocentesis in Asian populations has
rarely been described. Here, we document an 11-year
(1990–2000) experience of prenatal diagnosis of Down
syndrome by amniocentesis in the Taiwanese population.
Materials and Methods
Data were compiled in a database for 26 cytogenetic
laboratories (Appendix) in Taiwan and covered the
cytogenetic analyses of amniocytes from second-
trimester amniocenteses between 1990 and 2000. The
data provided a detailed account of the amniocentesis
results following the main indications of a family history
of chromosome aberrations, advanced maternal age,
abnormal maternal serum screening results, abnormal
ultrasound findings, a previous child with a congenital
anomaly, and other purposes. In some instances, there
were multiple indications. For investigative simplicity,
multiple indications were reduced to a single indica-
tion using the priority order above. A family history
of chromosome aberrations included a family history
of aneuploidy, translocation, inversion, or marker
chromosome. Advanced maternal age was defined as
more than 35 years old at delivery. Abnormal maternal
serum screening results included patients who were
screen-positive for Down syndrome and trisomy 18.
Taiwan began an active national policy of offering
amniocentesis to women aged at least 35 years and
those with indications other than age in 1990. A large-
scale, second-trimester maternal serum screening
double-marker testing program for Down syndrome
using the maternal serum markers _-fetoprotein (AFP),
human chorionic gonadotropin (hCG) or its variant
free `-hCG was implemented in 1994. Prior to 1994,
only maternal serum AFP was used for prenatal screening.
Abnormal ultrasound findings included anomalies and
ultrasound markers suggesting chromosomal ab-
normalities. Other purposes included an abnormally
high level of maternal serum AFP, prenatal biochemical
or molecular referrals, a history of spontaneous abortion,
and elective purposes such as anxiety, normal maternal
serum screening results close to a Down syndrome risk
cut-off level of 1/270, maternal age close to 35 years,
etc. Chromosome aberrations included autosomal
trisomies, triploidy, tetraploidy, mosaicism, ring
chromosomes, deletion, duplication, inversion,
balanced translocation, unbalanced translocation, and
marker chromosomes. Chromosome variants such as
inversion of chromosomes 9 and Y, double satellites or
marked satellite on acrocentric chromosomes, and
hyperchromatin on chromosomes 1, 9, and 16 were
categorized as normal. The Chi-squared test was used
to compare rates. A p value of less than 0.05 was
considered significant.
Results
From 1990 to 2000, 166,419 amniocenteses were
analyzed cytogenetically in the Taiwanese population
(Table 1). Among these, 58.85% were done for advanced
maternal age, 4.5% for abnormal ultrasound findings,
26.17% for abnormal maternal serum screening results,
1.82% for a previous child with a congenital anomaly,
1.02% for a family history of chromosome aberrations,
and 7.63% for other purposes. Chromosome aberrations
were detected in 4,217 cases (2.53%), of which 1,277
(30.28%) were Down syndrome. Of the Down syndrome
cases, 65.86% were detected by amniocentesis for
advanced maternal age, 5.95% for abnormal ultrasound
findings, 21.14% for abnormal maternal serum screening
results, 1.25% for a previous child with a congenital
anomaly, 1.18% for a family history of chromosome
aberrations, and 4.62% for other purposes (Table 2).
There was a prominent increase in the number of
women undergoing amniocentesis in the Taiwanese
population from 1990 to 2000. There was an 8.9-fold
increase in the group undergoing amniocentesis for
advanced maternal age (p < 0.01), a 6.3-fold increase in
those for abnormal ultrasound findings (p < 0.01), a
46.2-fold increase in those for abnormal maternal serum
screening results (p < 0.01), a 2.9-fold increase in those
for a previous child with a congenital anomaly (p <
0.05), a 5.6-fold increase in those for a family history of
chromosome aberrations (p < 0.01), and a 4.4-fold
increase in those undergoing amniocentesis for other
purposes (p < 0.05). There was also a 35.7-fold increase
in the number of prenatally detected Down syndrome
cases, from seven in 1990 to 250 in 2000 (p < 0.01).
The highest rates of Down syndrome were present
in women undergoing amniocentesis for abnormal
ultrasound findings (1/99 tests). Down syndrome was
0.72-fold as common in amniocenteses performed be-
cause of positive serum screening results (1/161 tests)
compared with the rate seen in the advanced maternal
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age group (1/116 tests). The detection rates increased
from 1/449 tests in 1990 to 1/123 tests in 2000 (Table
2).
Discussion
This study showed a significant increase in the number
of Down syndrome cases detected prenatally between
1990 and 2000 in the Taiwanese population. During
this period, there was also an increase in the number of
amniocenteses. The increase was especially prominent
after 1994, when maternal serum screening double-
marker testing was first applied in this population. The
increases in both the number of detected cases of
Down syndrome and the number of amniocenteses
were attributed to the national policy of offering
amniocentesis to women aged at least 35 years, the
introduction of maternal serum biochemical double-
marker testing, and the active application of prenatal
ultrasonography. While both the number of women
undergoing amniocentesis and the number of detected
cases of Down syndrome increased during these years,
the detection rates for Down syndrome remained
constant after 1998. This suggests that amniocentesis
in this population no longer led to a significant im-
provement in the detection rate of Down syndrome.
Therefore, more powerful screening programs such as
first-trimester maternal serum screening in conjunction
with nuchal translucency and nasal bone measurement
by early ultrasound examination are required.
On the other hand, in this population, a great
number of non-recommended amniocenteses were
performed for elective purposes such as anxiety, normal
maternal serum screening results that were close to a
Down syndrome risk cut-off level of 1/270, and a
maternal age nearing 35 years. This was partly due to
insufficient genetic counseling facilities and personnel
and partly due to changing family values that empha-
size the quality rather than quantity of children in this
population. The impact of maternal serum screening on
the birth prevalence of Down syndrome and on the use
of invasive genetic tests has been described in different
populations [1–6]. This 11-year Taiwanese experience
of prenatal diagnosis of Down syndrome shows that
the introduction of second-trimester maternal serum
screening programs resulted in increased use of am-
niocentesis and an increased number of prenatally de-
tected cases of Down syndrome but no improvement in
the detection rate of Down syndrome by amniocente-
sis in the end of this period. In view of the effective use
of amniocentesis as a diagnostic procedure for Down
syndrome, efforts should be made using more efficient
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prenatal screening programs and reducing the number
of unnecessary amniocenteses.
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